Diagnostic Performance of CLEIA Versus FEIA for KL-6 Peripheral and Alveolar Concentrations in Fibrotic Interstitial Lung Diseases: A Multicentre Study.
Krebs von den Lungen‐6
bronchoalveolar lavage
diagnosis
interstitial lung diseases
pulmonary fibrosis
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
revised:
06
09
2024
received:
15
07
2024
accepted:
14
09
2024
medline:
26
9
2024
pubmed:
26
9
2024
entrez:
26
9
2024
Statut:
aheadofprint
Résumé
Interstitial lung diseases (ILD) is a group of lung disorders characterized by interstitial lung thickening due to inflammatory and fibrotic processes. Krebs von den Lungen-6 (KL-6) is a molecule secreted by damaged type II alveolar pneumocytes in the alveolar space. The goal of the present study was to compare two detection methods of KL-6 in both bronchoalveolar lavage (BAL) and serum from ILD patients at the moment of diagnosis. Patients with suspicious of ILD and followed at two Italian referral centres for rare lung diseases were included in the study. BAL fluid and serum were collected and analysed by chemiluminescent enzyme immunoassay (CLEIA) and fluorescent enzyme immunoassay (FEIA) methods provided by Tosoh Biosciences. A total of 158 (mean age ± standard deviation, 61.5 ± 13.7, 65 females) patients were enrolled. A total of, 36 had diagnosis of idiopathic pulmonary fibrosis (IPF), 74 sarcoidosis, 15 connective tissue disease-ILD (CTD-ILD) and 33 other ILD. Diagnostic agreement between two methods was demonstrated for both BAL (r = 0.707, p < 0.0001) and serum (r = 0.816, p < 0.0001). BAL KL-6 values were lower than serum (p < 0.0001). IPF patients had higher serum KL-6 concentration than other ILDs (p = 0.0294), while BAL KL-6 values were lower in IPF than in non-IPF (p = 0.0023). This study explored KL-6 concentrations through the CLEIA method in serum and BAL of patients with various ILDs, showing significant differences of biomarkers concentrations between IPF and other non-IPF ILDs. Our findings are promising as they provided further knowledge concerning KL-6 expression across different ILDs and may suggest its utility in differential diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Interstitial lung diseases (ILD) is a group of lung disorders characterized by interstitial lung thickening due to inflammatory and fibrotic processes. Krebs von den Lungen-6 (KL-6) is a molecule secreted by damaged type II alveolar pneumocytes in the alveolar space. The goal of the present study was to compare two detection methods of KL-6 in both bronchoalveolar lavage (BAL) and serum from ILD patients at the moment of diagnosis.
METHODS
METHODS
Patients with suspicious of ILD and followed at two Italian referral centres for rare lung diseases were included in the study. BAL fluid and serum were collected and analysed by chemiluminescent enzyme immunoassay (CLEIA) and fluorescent enzyme immunoassay (FEIA) methods provided by Tosoh Biosciences.
RESULTS
RESULTS
A total of 158 (mean age ± standard deviation, 61.5 ± 13.7, 65 females) patients were enrolled. A total of, 36 had diagnosis of idiopathic pulmonary fibrosis (IPF), 74 sarcoidosis, 15 connective tissue disease-ILD (CTD-ILD) and 33 other ILD. Diagnostic agreement between two methods was demonstrated for both BAL (r = 0.707, p < 0.0001) and serum (r = 0.816, p < 0.0001). BAL KL-6 values were lower than serum (p < 0.0001). IPF patients had higher serum KL-6 concentration than other ILDs (p = 0.0294), while BAL KL-6 values were lower in IPF than in non-IPF (p = 0.0023).
CONCLUSION
CONCLUSIONS
This study explored KL-6 concentrations through the CLEIA method in serum and BAL of patients with various ILDs, showing significant differences of biomarkers concentrations between IPF and other non-IPF ILDs. Our findings are promising as they provided further knowledge concerning KL-6 expression across different ILDs and may suggest its utility in differential diagnosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25108Informations de copyright
© 2024 The Author(s). Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
J. Behr, “Approach to the Diagnosis of Interstitial Lung Disease,” Clinics in Chest Medicine 33, no. 1 (2012): 1–10.
V. Cottin, L. Wollin, A. Fischer, M. Quaresma, S. Stowasser, and S. Harari, “Fibrosing Interstitial Lung Diseases: Knowns and Unknowns,” European Respiratory Review 28, no. 151 (2019): 180100.
T. Geiser and S. Guler, “Diagnosis of ILD,” Therapeutische Umschau 73, no. 1 (2016): 7–10.
W. D. Travis, U. Costabel, D. M. Hansell, et al., “An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias,” American Journal of Respiratory and Critical Care Medicine 188, no. 6 (2013): 733–748.
T. Karampitsakos, B. M. Juan‐Guardela, A. Tzouvelekis, and J. D. Herazo‐Maya, “Precision Medicine Advances in Idiopathic Pulmonary Fibrosis,” eBioMedicine 95 (2023): 104766.
N. Kohno, S. Kyoizumi, Y. Awaya, H. Fukuhara, M. Yamakido, and M. Akiyama, “New Serum Indicator of Interstitial Pneumonitis Activity. Sialylated Carbohydrate Antigen KL‐6,” Chest 96, no. 1 (1989): 68–73.
N. Kohno, Y. Awaya, T. Oyama, et al., “KL‐6, a Mucin‐Like Glycoprotein, in Bronchoalveolar Lavage Fluid From Patients With Interstitial Lung Disease,” American Review of Respiratory Disease 148, no. 3 (1993): 637–642.
P. Sivapalan, B. Bonnesen, and J. U. Jensen, “Novel Perspectives Regarding the Pathology, Inflammation, and Biomarkers of Acute Respiratory Distress Syndrome,” International Journal of Molecular Sciences 22, no. 1 (2020): 205.
A. Yokoyama, N. Kohno, K. Kondo, et al., “Comparative Evaluation of Sialylated Carbohydrate Antigens, KL‐6, CA19‐9 and SLX as Serum Markers for Interstitial Pneumonia,” Respirology 3, no. 3 (1998): 199–202.
K. Borensztajn, B. Crestani, and M. Kolb, “Idiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers—Insights From the Bench Side,” Respiration 86, no. 6 (2013): 441–452.
N. Ishikawa, N. Hattori, A. Yokoyama, and N. Kohno, “Utility of KL‐6/MUC1 in the Clinical Management of Interstitial Lung Diseases,” Respiratory Investigation 50, no. 1 (2012): 3–13.
T. Zhang, P. Shen, C. Duan, and L. Gao, “KL‐6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta‐Analysis,” Frontiers in Immunology 12 (2021): 745233.
H. Satoh, K. Kurishima, H. Ishikawa, and M. Ohtsuka, “Increased Levels of KL‐6 and Subsequent Mortality in Patients With Interstitial Lung Diseases,” Journal of Internal Medicine 260, no. 5 (2006): 429–434.
P. Soccio, G. Moriondo, M. d'Alessandro, et al., “Role of BAL and Serum Krebs von den Lungen‐6 (KL‐6) in Patients With Pulmonary Fibrosis,” Biomedicine 12, no. 2 (2024): 269.
M. d'Alessandro, L. Bergantini, D. Cavallaro, et al., “Krebs von den Lungen‐6 as Disease Severity Marker for COVID‐19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA‐360 Compared to Lumipulse G600II,” International Journal of Environmental Research and Public Health 19, no. 4 (2022): 2176.
U. Costabel and G. W. Hunninghake, “ATS/ERS/WASOG Statement on Sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders,” European Respiratory Journal 14, no. 4 (1999): 735–737.
D. Aletaha, T. Neogi, A. J. Silman, et al., “2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative,” Annals of the Rheumatic Diseases 69, no. 9 (2010): 1580–1588.
F. van den Hoogen, D. Khanna, J. Fransen, et al., “2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative,” Annals of the Rheumatic Diseases 72, no. 11 (2013): 1747–1755.
C. H. Shiboski, S. C. Shiboski, R. Seror, et al., “2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts,” Arthritis & Rhematology 69, no. 1 (2017): 35–45.
B. H. Culver, B. L. Graham, A. L. Coates, et al., “Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement,” American Journal of Respiratory and Critical Care Medicine 196, no. 11 (2017): 1463–1472.
P. L. Haslam and R. P. Baughman, “Report of ERS Task Force: Guidelines for Measurement of Acellular Components and Standardization of BAL,” European Respiratory Journal 14, no. 2 (1999): 245–248.
N. Kohno, H. Hamada, S. Fujioka, K. Hiwada, M. Yamakido, and M. Akiyama, “Circulating Antigen KL‐6 and Lactate Dehydrogenase for Monitoring Irradiated Patients With Lung Cancer,” Chest 102, no. 1 (1992): 117–122.
H. Hamada, N. Kohno, M. Akiyama, and K. Hiwada, “Monitoring of Serum KL‐6 Antigen in a Patient With Radiation Pneumonia,” Chest 101, no. 3 (1992): 858–860.
P. Millan‐Billi, I. Castellví, L. Martinez‐Martinez, et al., “Diagnostic Value of Krebs von den Lungen (KL‐6) for Interstitial Lung Disease: A European Prospective Cohort,” Archivos de Bronconeumología 60 (2024): 350–355.
T. Sarycheva, N. Capkova, A. Pająk, et al., “Impaired Lung Function and Mortality in Eastern Europe: Results From Multi‐Centre Cohort Study,” Respiratory Research 23, no. 1 (2022): 140.
S. Hisata, Y. Kimura, N. Shibata, et al., “A Normal Range of KL‐6/MUC1 Independent of Elevated SP‐D Indicates a Better Prognosis in the Patients With Honeycombing on High‐Resolution Computed Tomography,” Pulmonary Medicine 2011 (2011): 806014.
M. d'Alessandro, A. Carleo, P. Cameli, et al., “BAL Biomarkers' Panel for Differential Diagnosis of Interstitial Lung Diseases,” Clinical and Experimental Medicine 20, no. 2 (2020): 207–216.
M. d'Alessandro, L. Bergantini, P. Cameli, et al., “Serum KL‐6 Levels in Pulmonary Langerhans' Cell Histiocytosis,” European Journal of Clinical Investigation 50, no. 8 (2020): e13242.
M. d'Alessandro, L. Bergantini, P. Cameli, et al., “Serum Concentrations of KL‐6 in Patients With IPF and Lung Cancer and Serial Measurements of KL‐6 in IPF Patients Treated With Antifibrotic Therapy,” Cancers 13, no. 4 (2021): 689.
A. P. Lopes, M. A. Mineiro, F. Costa, et al., “Portuguese Consensus Document for the Management of Alpha‐1‐Antitrypsin Deficiency,” Pulmonology 24 Suppl 1 (2018): 1–21.
S. Majewski, K. Szewczyk, A. Żal, A. J. Białas, J. Miłkowska‐Dymanowska, and W. J. Piotrowski, “Serial Measurements of Circulating KL‐6, SP‐D, MMP‐7, CA19‐9, CA‐125, CCL18, and Periostin in Patients With Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study,” Journal of Clinical Medicine 10, no. 17 (2021): 3864.